Back to search

Article

Differential Transcriptomic Modulation by Histone Deacetylase Inhibitor SAHA in LUAD and LUSC

2025-08-21

Abstract excerpt

<title>Abstract</title> <p> Background Histone deacetylases (HDACs) drive non-small cell lung cancer (NSCLC) progression, yet HDAC inhibitor (HDACi) responses vary by tumor subtype. We compared the pan-HDAC inhibitor suberoylanilide hydroxamic acid (SAHA, vorinostat) in two NSCLC models-HER2-mutant lung adenocarcinoma (NCI-H1299; TP53 <sup>del</sup> , NRAS <sup>Q61K</sup> ) and EGFR/PI3K-driven squamous carc...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
5ebde688-4f63-598c-887c-93f66cfee9e4
DOI
10.21203/rs.3.rs-7322428/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Differential Transcriptomic Modulation by Histone Deacetylase Inhibitor SAHA in LUAD and LUSCDOI 10.21203/rs.3.rs-7322428/v1
A Novel Histone Deacetylase Inhibitor Exhibits Antitumor Activity via Apoptosis Induction, F-Actin Disruption and Gene Acetylation in Lung CancerSemantic proximity
Antitumor effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid in epidermal growth factor receptor-mutant non-small-cell lung cancer lines in vitro and in vivo.Semantic proximity
Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer.Semantic proximity
HDAC and HDAC Inhibitor: From Cancer to Cardiovascular DiseasesSemantic proximity
Low-dose SAHA enhances CD8+ T cell-mediated antitumor immunity by boosting MHC I expression in non-small cell lung cancerSemantic proximity
Histone Deacetylase Inhibitors: Development of Suberoylanilide Hydroxamic Acid (SAHA) for the Treatment of CancersSemantic proximity
Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4+ T cellsSemantic proximity
A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective Against Hepatocellular Carcinoma and Induces Durable Responses with ImmunotherapySemantic proximity
A novel approach to detect resistance mechanisms reveals FGR as a factor mediating HDAC inhibitor SAHA resistance in B-cell lymphoma.Semantic proximity
Novel hydroxamic acid derivative induces apoptosis and constrains autophagy in leukemic cellsSemantic proximity
Targeting histone deacetylases for the treatment of cancer and inflammatory diseasesSemantic proximity
Suberoylanilide Hydroxamic Acid (SAHA) Treatment Reveals Crosstalk Among Proteome, Phosphorylome and Acetylome in Nasopharyngeal Carcinoma CellsSemantic proximity
Select a neighboring publication to make it the new centre.